SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Interest Income

Income earned on cash, deposits, and investments held by the company.

SNDL Inc.NASDAQ: SNDL

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was CA$0, compared with CA$3.02M a year earlier. Trailing-twelve-month interest income was CA$5.03M. Over 3 fiscal years it compounded at -23.0% a year.

Context

  • Interest income amounted to 0.9% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$1.26M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0-100.0% QoQ
Last fiscal yearDec 2025
CA$8.05M-50.9% YoY
LTMMar 2026
CA$5.03M-77.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-50.9%——
3-year CAGR-23.0%——
5-year CAGR——
10-year CAGR——

Interest Income history

CAD · from the income statement

Latest · FY2025
8.05M CAD
Year-over-year change
-50.9%
4-year CAGR
-12.5%

Interest Income vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -77.6% is the 6th highest of 8, against a peer median of -14.2%.
  • Interest income amounts to 0.5% of revenue for SNDL, versus a peer median of 0.3%.
SNDL Competitors
Interest Income for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.48M USD+18.9%+93.8%—
CMPSCOMPASS Pathways plcLTM Mar 2026$7.2M USD-14.2%——
SNDLSNDL Inc.LTM Mar 2026CA$5.03M CAD-77.6%-23.0%0.5%
SIGASIGA Technologies, Inc.LTM Mar 2026$4.41M USD+161.5%—4.7%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$1.7M USD+76.9%—0.3%
EOLSEvolus, Inc.LTM Mar 2026$1.51M USD-56.4%+153.2%0.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$1.1M USD——0.3%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$0 USD——0.0%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$525K USD-125.8%+56.5%—
Peer median (excluding SNDL) —-14.2%+93.8%0.3%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.